Details About Generic Salt ::  Cefepime

Main Medicine Class::    

Class: Antibiotic/cephalosporin


Drugs Class ::

 Action Inhibits mucopeptide synthesis in bacterial cell wall.

Indications for Drugs ::

 Indications Treatment of pneumonia and infections of the skin and skin structures and urinary tract due to susceptible strains of specific microorganisms. Treatment of empiric therapy for febrile neutropenic patients as monotherapy. Treatment for complicated intra-abdominal infections in combination with metronidazole.

Drug Dose ::


Mild-to-Moderate Uncomplicated or Complicated Urinary Tract Infections

ADULTS: IV/IM 0.5 to 1 g q 12 hr for 7 to 10 days.

Severe Uncomplicated or Complicated Urinary Tract Infections

ADULTS: IV 2 g q 12 hr for 10 days.

Moderate-to-Severe Pneumonia

ADULTS: IV 1 to 2 g q 12 hr for 10 days.

Moderate-to-Severe Uncomplicated Skin and Skin Structure Infections

ADULTS: IV 2 g q 12 hr for 10 days CHILDREN < 40 KG: 50 mg/kg/dose every 12 hr (every 8 hr for febrile neutropenic patients) for 7 to 10 days. Do not exceed the recommended adult dose.

Children with Renal Impairment

Data not available; however, changes in dosing regimen similar to those in adults are recommended.

Contraindication ::

 Contraindications Hypersensitivity to cephalosporins, penicillins, or other beta-lactam antibiotics.

Drug Precautions ::


Pregnancy: Category B. Lactation: Excreted in breast milk. Children: Safety and efficacy in children < 12 yr have not been established. Renal impairment: Dosage adjustment is necessary in patients with creatinine clearance < 60 ml/min. Hypersensitivity: Reactions range from mild to life-threatening. Administer drug with caution to penicillin-sensitive patients due to possible cross-sensitivity. Pseudomembranous colitis: Should be considered in patients in whom diarrhea develops. Superinfection: Drug may cause bacterial or fungal overgrowth of nonsusceptible microorganisms.


Drug Side Effects ::

 Adverse Reactions

CNS: Headache. GI: Nausea; vomiting; diarrhea; colitis; including pseudomembranous colitis; oral moniliasis. DERM: Rash; pruritis; urticaria. OTHER: Hypersensitivity, including Stevens-Johnson syndrome; erythema multiforme; toxic epidermal necrolysis; candidal overgrowth; serum sickness-like reactions (eg, skin rashes, polyarthritis, arthralgia, fever); phlebitis; pain or inflammation at injection site; fever.

Drug Mode of Action ::  

 Action Inhibits mucopeptide synthesis in bacterial cell wall.

Drug Interactions ::


Aminoglycosides: Increased risk of nephrotoxicity and ototoxicity. INCOMPATIBILITIES: Metronidazole, vancomycin, gentamicin, tobramycin, netilmicin, aminophylline and ampicillin (> 40 mg/ml).

Drug Assesment ::


  • Obtain patient history, including drug history and any known allergies. Note allergy to cephalosporins and penicillins.
  • Obtain specimens for culture and sensitivity before beginning therapy and periodically during treatment.
  • Monitor for signs of infection, especially fever, and for positive response to antibiotic therapy.
  • Assess for signs and symptoms of anaphylaxis (eg, shortness of breath, wheezing, laryngeal spasm). Have resuscitation equipment available.
  • Assess for signs of superinfection, such as vaginitis or stomatitis.
  • Assess for diarrhea with blood or pus, which may be a symptom of pseudomembranous colitis. Symptoms may occur after antibiotic treatment.
  • Monitor IV site for infiltration, infection, and thrombophlebitis.
  Seizures, encephalopathy, neuromuscular excitability

Drug Storage/Management ::


  • IM rate indicated only for mild-to-moderate, uncomplicated, or complicated UTIs due to E. coli.
  • Inject IM preparations deep into large muscle groups.
  • Dilute IV preparations with 50 to 100 ml of compatible IV fluid and administer over 30 min.
  • Do not administer if particulate matter is noted in reconstituted solution.
  • Store unopened vials at room temperature (68° to 77°F). Store reconstituted solutions at room temperature (68° to 77°F) for up to 24 hours or refrigerated (36° to 46°F) for up to 7 days.
  • Protect from light.

Drug Notes ::

 Patient/Family Education

  • Instruct patient to check body temperature daily. If fever persists for more than a few days or if high fever (> 102°F) or shaking chills are noted, physician should be notified immediately.
  • Advise patient to maintain normal fluid intake while using this medication.
  • Advise patient to report signs of superinfection: Black “furry” tongue, white patches in mouth, foul-smelling stools, vaginal itching, or discharge.
  • Instruct patient in good personal hygiene (especially mouth and perineal care).
  • Advise patient to report any increase in ecchymoses, petechiae, or nose bleeds.
  • Advise patient to eat/drink 4 oz of yogurt or buttermilk a day as a prophylaxis against intestinal superinfection.
  • Advise diabetic patient to use enzyme-based tests (eg, Clinistix, Testape) for monitoring urine glucose because drug may give false results with other tests.
  • Instruct patient to report these symptoms to physician: Nausea, vomiting, diarrhea, skin rash, hives, sore throat, bruising, bleeding, muscle or joint pain.
  • Warn patient that diarrhea containing blood or pus may be a sign of serious disorders.
  • Tell patient to seek medical care for symptoms and not to treat at home. Instruct patient to seek emergency care if wheezing or difficulty in breathing occurs.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.


One of the 1st in India.High Quality Generic Medicine Portal Android Application for Online Oreder & Information.

For More Join Our Membership and Get Additional 25% off on Meds, also get MLM Benefits to get a permanent earning source.

Join Membership How to Search Medicine
Android App

We would like to keep you updated with special notifications.